cyclophosphamide; hemorrhagic cystitis; nitric oxide; uric acid Background/Purpose: Hemorrhagic cystitis is a common complication with chemotherapeutic alkylating agents. We investigated the possible prognostic factors of cyclophosphamideinduced hemorrhagic cystitis in children. Methods: Medical records of children (< 18 years old) with cyclophosphamide-related hemorrhagic cystitis were collected retrospectively from January 2000 to December 2010 in a tertiary care center. We also prospectively enrolled children (< 18 years old) with cyclophosphamide treatment. Results: The retrospective study consisted of 23 patients whose median age was 11 years. The median day of onset time was 1 day after cyclophosphamide usage. The hemato-oncological diseases included acute leukemia (39.1%), lymphoma (13%), blastoma (13%), sarcoma (13%), aplastic anemia (13%), and others (8.7%). Patients who received bone marrow transplantation (BMT) had significantly longer duration of hemorrhagic cystitis than those who did not receive BMT (p < 0.05). Serum uric acid, checked prior to and after the onset of hemorrhage cystitis, was significantly lower after the development of hemorrhagic cystitis (p < 0.05). In the prospective study, 11 children were enrolled with a median age of 5 years. The urinary nitrite/nitrate and 8-iso-prostaglandin F2a levels increased significantly after cyclophosphamide usage (p < 0.05). Conclusion: Alteration serum uric acid level and BMT could be indicators for severe hemorrhagic cystitis. The elevated levels of urinary nitrite/nitrate and 8-iso-prostaglandin F2a may indicate the essential roles played by nitric oxide syntheses and reactive oxidative stress in cyclophosphamide-induced hemorrhagic cystitis. These findings may help clinicians formulate a better strategy for treating cyclophosphamide-induced hemorrhagic cystitis.
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Introduction
Cyclophosphamide is a common alkylating antineoplastic agent for chemotherapy 1, 2 with the common side effect of causing hemorrhagic cystitis in children. 3 Complications of cyclophosphamide include urothelial damage with bladder edema, ulceration, neovascularization, hemorrhage, and necrosis. Incidence rates between 7% and 70% have been reported in children with hemorrhagic cystitis. 4, 5 There are often marked morbidities and mortalities with severe hemorrhagic cystitis in children. Mesna (2-mercaptoethane sulfonate), high fluid intake, diuretics, and urine alkalinization are the most common treatment strategies for the prevention of hemorrhagic cystitis.
6e8 However, cyclophosphamideinduced hemorrhagic cystitis is still significantly noted even after this side effect has been clinically managed.
Although previous studies suggested the potential mechanism of hemorrhagic cystitis in children with chemotherapy, the data are limited and the prognostic factors remain to be established.
9e11 Inducible NO synthase (iNOS) was originally induced by inflammatory mediators in variable cell types, 12 and hemorrhagic cystitis has been found to induce iNOS expression in the urinary bladder of rats. 13 In addition, 8-isoprostaglandin F2a produced by free radical-induced peroxidation of arachidonic acid are widely used as a biomarker of peroxidation and oxidative stress in adults.
14 According to previous studies, urinary 8-iso-prostaglandin F 2a levels served as the reactive oxidative stress indicator of oxidative severity in asthma, chronic obstructive pulmonary disease, interstitial lung disease, and renal injury. 15, 16 Abraham and Isaac 17 found that increased malondialdehyde could serve as the oxidative stress parameter in the kidneys of rats after treatment with cyclophosphamide. However, little information is available about the severity assessment and predictor of cyclophosphamide-induced hemorrhagic cystitis. The implication of NOS and reactive oxidative species (ROS), BMT Z bone marrow transplantation; BUN/Cre Z blood urea nitrogen/creatinine; CYC Z cysclophosphamide; IV Z intravenous; Late death Z death within 1 year; N Z no data.
which mediates the cyclophosphamide-induced hemorrhagic cystitis, in the evaluation of the severity and predictor of hemorrhagic cystitis has never been clinically studied. This study investigated the prognostic factors of hemorrhagic cystitis in children aged from 2 months to 18 years with cyclophosphamide usage and further evaluated the urinary nitrite/nitrate (NO x ) and 8-iso-prostaglandin F a levels in oncology children who received cyclophosphamide treatment.
Materials and methods
This was a combined retrospective review and prospective pilot study of children. The diagnosis of hemorrhagic cystitis was identified in this tertiary referral center between 2000 and 2010. The inclusion criteria were patients who were younger than 18 years and receiving cyclophosphamide with clinical hematuria and positive urine analysis. The exclusion criteria were patients who were older than 18 years, with possible infection associated with hemorrhagic cystitis, an onset time of more than 30 days after receiving cyclophosphamide, and those presenting with urinary tract infection or other congenital urinary tract anomalies. The medical records of patients, including age at presentation, symptoms, associated medication, biochemical profiles, dosage of chemotherapy, onset time, and duration of hemorrhagic cystitis and outcomes, were reviewed. A total of 15 age-matched patients with a similar underlying disease but without hemorrhagic cystitis after cyclophosphamide treatment were selected from our database from January 2000 to December 2010. In the pilot study, 11 children undergoing cyclophosphamide treatment were invited to participate in this tertiary referral center from January 2011 to December 2011. Spot urine was checked prior to and after treatment, and its analysis was performed to ascertain the diagnosis of hemorrhagic cystitis via urine multisticks. If the spot urinary analysis showed hematuria or gross hematuria, hemorrhagic cystitis was diagnosed. We collected urine samples from patients prior to and after chemotherapy sessions at varying intervals, e4e0 hours, 0e4 hours, 4e12 hours, and 12e24 hours, for a total of four fractions. Nitrite plus nitrate concentration nitrite/nitrate (NO x ) and 8-iso-prostaglandin F2a levels were determined in urine with the Griess method using automated commercial kits (R&D Systems, Minneapolis, MN, USA) as previously described. 18 Urine was passed over a cadmium column that reduces nitrate to nitrite. Subsequently, nitrite was combined with Griess reagent to form a red azo dye that was measured spectrophotometrically at 538 nm. Urinary 8-iso-prostaglandin F2a was measured with an enzyme immunoassay using commercial kits (Cayman Chemicals, Ann Arbor, MI, USA) that is read spectrophotometrically at 450 nm. Urinary creatinine concentrations were measured using an automated colorimetric method. To avoid variance among different lots, kits from the same lot were used for measurement. The levels were standardized with urinary creatinine. The procedures for sample handling and assay were performed in accordance with the manufacturer's instructions. All assays were performed in duplicate. Descriptive statistics were applied, and nominal variables were presented as mean or median with ranges as indicated.
This study was approved by the Institutional Ethics Committee of National Taiwan University Hospital, Taipei, Taiwan (NTUH201008052R), and each participant provided written consent prior to participation.
Statistical analysis
All data are expressed as mean AE standard error of the mean. Paired Student t test was used to evaluate possible differences in clinical data. Significant differences from the respective controls for each experimental test condition were assessed using one-way analysis of variance, and Bonferroni t-test with p < 0.05 was considered significant.
Results

Demographic data in children with hemorrhagic cystitis
A total of 23 patients with cyclophosphamide treatment and induction of hemorrhagic cystitis were included. The incidence of hemorrhagic cystitis with cyclophosphamide treatment in children in our hospital is 2.6 %. The characteristic features of these 23 patients are summarized in Table 1 . The median age at diagnosis was 11 years (range, 3e17 years). The male/female ratio was 1.1:1. The median amount of days of onset time was approximately 1 day after cyclophosphamide usage. The median amount of days for the duration of hemorrhagic cystitis was 9 days. The distribution of hemato-oncological disease in these patients included acute leukemia (n Z 9, 39.1%), lymphoma (n Z 3, 13%), blastoma (n Z 3, 13%), sarcoma (n Z 3, 13%), aplastic anemia (n Z 3, 13%), and other (n Z 2, 8.7%). The mean of the total cyclophosphamide dose was approximately 4697 mg. Of the patients who received bone marrow transplantation (BMT), the duration of hemorrhagic cystitis was significantly longer than that of the patients who did not receive BMT (p < 0.05; Fig. 1A ). Among them, 16 patients underwent complete blood sampling with uric acid detection prior to receiving chemotherapy and after hemorrhagic cystitis. One patient received oral allopurinol to treat hyperuricemia; the others did not receive any medication to decrease the level of uric acid. Fifteen patients underwent blood sampling with a mean level of uric acid being 4.9 mg/dL prior to chemotherapy and the mean level of uric acid being 2.6 mg/dL after hemorrhagic cystitis. In the control group, age and sex were matched. In terms of age, paired Student t test showed no significant difference (p Z 0.39) between the study and the control groups. Total cyclophosphamide dose in both groups also showed no significant difference (p Z 0.29). Results of the comparison of uric acid levels prior to and after cyclophosphamide treatment with the control group is summarized in Table 2 . The higher uric acid level in the control group compared to that in the study group in post-cyclophosphamide treatment was noted (p < 0.05), and a similar trend was noted in pre-cyclophosphamide treatment but without significant difference (p Z 0.17). Comparing the levels of serum uric acid prior to and after the induction of hemorrhagic cystitis showed significantly lower levels of uric acid in patients after hemorrhagic cystitis induction (p < 0.05; Fig. 1B) . A lower level of serum uric acid after chemotherapy was correlated with patients receiving BMT (p < 0.05; Fig. 1C ). Three patients (13%) in the study group expired during the hospital course, and six patients expired within 1 year.
Urine NO and 8-iso-prostaglandin F2a levels in children with cyclophosphamide chemotherapy Eleven patients whose age ranged from 4 years to 17 years were included in the pilot study. The male/female ratio was 1.7:1. No obvious hemorrhagic cystitis was noted during chemotherapy. The urinary nitrite/nitrate levels were significantly increased at the fractions of 0e4 hours and 4e12 hours after cyclophosphamide usage (p < 0.05) and then gradually decreased at 12e24 hours ( Fig. 2A) . The levels of 8-iso-prostaglandin F2a at the fractions of 4e12 hours and 12e24 hours were elevated significantly (Fig. 2B ).
Discussion
Our study showed that: (1) the level of urinary NO x increased after cyclophosphamide treatment, which is compatible with a previous animal study; 19 (2) oxidative stress, as indicated by 8-iso-prostaglandin F2a, was increased after cyclophosphamide treatment; and (3) uric acid and BMT seem to play important roles in cyclophosphamide-induced hemorrhagic cystitis. Hemorrhagic cystitis poses a significant issue for children undergoing chemotherapy. Previous studies have shown that a high incidence of hemorrhagic cystitis appears in children receiving conditioning chemotherapy during BMT. 20, 21 In their report, Dr Lin and his colleagues 22 noted that the condition of one of the six children with acute myelogenous leukemia was complicated with hemorrhagic cystitis after BMT. Although the current studies showed that the common complication after hematopoietic stem cell transplantation in Taiwan included graft-versus-host disease, viral hepatitis, tuberculosis, cytomegalovirus infection, or pulmonary dysfunction, 23e25 acute kidney injury was also an important outcome predictor. 26 However, only a few studies have discussed hemorrhagic cystitis in Taiwanese children. In the present study, we reviewed hemorrhagic cystitis in children over the past 10 years and found that BMT may be a potential risk factor for hemorrhagic cystitis. However, the actual role of BMT has yet to be fully elucidated; its positive results could have been caused by accumulation dosage or combined medical interaction. 27 We also found that uric acid may have been beneficial to these children, a finding similar to that found in a previous study examining patients with multiple sclerosis. 28 Our clinical review showed that the levels of serum uric acid decreased after an episode of hemorrhagic cystitis in children receiving cyclophosphamide. Lower levels of uric acid after hemorrhagic cystitis were associated with children receiving BMT. These findings prompted us to reevaluate the optimal level of uric acid in children undergoing chemotherapy. Although a high level of uric acid is usually connected to the disease gout and may compromise health, there are studies that report the antioxidant properties of uric acid. 29, 30 Shimada et al 31 also found a direct and an indirect role of uric acid in acute kidney injuries.
Cyclophosphamide has been well known as a chemotherapeutic agent since 1957. Hemorrhagic cystitis was later reported to be a significant complication in patients treated with cyclophosphamide. 32 The mechanism of cyclophosphamide-induced hemorrhagic cystitis was widely investigated, but it seems to be multifactorial and not related to the dosage of cyclophosphamide administered. 27, 33 There is evidence to prove the role of NO in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis. 5, 19, 34 There are several animal models for cyclophosphamide-related hemorrhagic cystitis, which include the intraperitoneal injection of cyclophosphamide in rats or mice, 13 directly injecting acrolein into the bladder by direct incision, 4, 35 or modified instilling acrolein into the bladder by a small urethral tube. 19 Significant induction of iNOS expression in bladders during cyclophosphamide-induced hemorrhagic cystitis was also observed. 3e5,32 In this study, we examined NO x (nitrate/nitrite) in the urinary bladder that indicated iNOS production. The results showed the increase of level at the fraction of 0e4 hours and decrease at the fraction of 12e12 hours, which is compatible with the results of previous animal study. 19 It also indicated the important role of iNOS production in children undergoing cyclophosphamide treatment.
However, there are several proposed hypotheses for cyclophosphamide-related hemorrhagic cystitis. It has been shown that antioxidant glutathione prevents acroleininduced hemorrhagic cystitis in mice. 4, 34 The increase in levels of ROS and NO has also been found during cyclophosphamide-induced hemorrhagic cystitis. 34 The Figure 2 Urinary levels of (A) NO x (nitrite/nitrate) and (B) 8-iso-prostaglandin F2a in children receiving cyclophosphamide treatment. Urine samples were collected from children prior to (e4e0 hours) and after (0e4 hours, 4e12 hours, and 12e24 hours) cyclophosphamide treatment. Data are presented as mean AE standard error of the mean (n Z 11). *p < 0.05 as compared with the e4e0 hours group. **p < 0.05 as compared with the 0e4 hour group.
overproduction of NO and ROS may lead to the formation of peroxynitrite, triggering damage of cellular macromolecules. 34, 36 In our study, the biomarker of oxidative stress, 8-iso-prostaglandin F2a, was also significantly elevated after children underwent cyclophosphamide treatment. Mediators composed of interleukins (IL-6, IL-1b) or tumor necrosis factor-a were studied as factors that participate in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis. 19, 37 Urinary bladder inflammation and overactivity were proven to be related to nuclear factor-kB activation in a cyclophosphamide-induced hemorrhagic cystitis rat model. 38 The clinical observation of the concentration of uric acid and 8-isoprostane in children may remind us of the essential role of ROS in cyclophosphamideinduced cystitis.
In conclusion, the results of this retrospective review study showed that the prevention of hemorrhagic cystitis may be very important for children who are receiving BMT. The alteration in levels of uric acid could be highly associated with hemorrhagic cystitis in children receiving cyclophosphamide treatment; the level of urinary NO x accompanying 8-iso-prostaglandin F2a increased significantly. In addition, NOS and ROS may both play an essential role in the development of cyclophosphamide-induced hemorrhagic cystitis. Taken together, uric acid may provide a protective mechanism in the case of cyclophosphamide-triggered hemorrhagic cystitis. The findings derived from the clinical observations in this study may help us formulate a better strategy for treating cyclophosphamide-induced hemorrhagic cystitis in children.
